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Heart
Impact of Treatment on Myocardial Lysyl Oxidase
Expression and Collagen Cross-Linking in Patients With
Heart Failure
Begon˜a Lo´pez, Ramo´n Querejeta, Arantxa Gonza´lez, Javier Beaumont, Mariano Larman, Javier Díez
Abstract—The aim of this study was to investigate whether torasemide modifies collagen cross-linking in the failing human
heart. We analyzed the degree of cross-linking and the expression of the enzyme lysyl oxidase, which regulates
cross-linking, in the myocardium of patients with chronic heart failure at baseline and after 8 months of treatment with
either torasemide or furosemide in addition to their standard heart failure therapy. Whereas lysyl oxidase protein
expression was very scarce in normal hearts, it was highly expressed in failing hearts. Cross-linking was increased
(P0.001) in heart failure patients compared with normal hearts. These 2 parameters decreased (P0.021 and
P0.034) in torasemide-treated patients and remained unchanged in furosemide-treated patients. In addition, more
(P0.009) patients showed normalization of left ventricular chamber stiffness in the torasemide subgroup than in the
furosemide subgroup after treatment. Lysyl oxidase expression correlated with cross-linking (r0.661; P0.001), and
cross-linking correlated with left ventricular chamber stiffness (r0.452; P0.002) in all patients. These findings show
for the first time that lysyl oxidase overexpression is associated with enhanced collagen cross-linking in the failing
human heart. In addition, we report that the ability of torasemide to correct both lysyl oxidase overexpression and
enhanced collagen cross-linking results in normalization of left ventricular chamber stiffness in patients with heart
failure. Lysyl oxidase may thus represent a target for reduction of stiff collagen and improvement of left ventricular
mechanical properties in heart failure patients. (Hypertension. 2009;53:236-242.)
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Myocardial fibrosis may contribute to the increased riskof chronic heart failure (HF) in patients with cardiac
diseases.1 A linkage between fibrosis and left ventricular
(LV) dysfunction/failure may be established through different
pathways, including increased passive stiffness that impairs
diastolic function.2 Several studies using experimental
models of pressure overload have demonstrated that LV
chamber stiffness is affected by changes in both myocar-
dial collagen quantity and quality, with the effect of
changes in collagen concentration being modified by the
degree of cross-linking.3– 6
Several steps are involved in the process leading to
exaggerated collagen deposition and fibrosis. Collagen is
synthesized and secreted by fibroblasts and myofibroblasts as
a procollagen precursor having amino-terminal and carboxy-
terminal propeptides that are cleaved to yield the triple helical
monomers of collagen by specific procollagen proteinases.7
After these proteolytic reactions, the collagen molecules are
rapidly and spontaneously assembled into collagen fibrils.
Chemical reactions slowly take place within existing collagen
fibrils in tissues, leading to formation of covalent bonds
between adjacent polypeptide chains and thus making the
final collagen fibers less soluble in any solvent and more
resistant against proteolytic enzymes. The first step in this
reaction sequence is enzymatic: the copper (Cu)-dependent
amine oxidase lysyl oxidase (LOX) catalyzes the oxidation of
the -amino groups in lysine or hydroxylysine residues,
resulting in the formation of corresponding aldehydes. Two
such aldehydes can then spontaneously react with each other,
or one aldehyde can bind to another –amino group; both
mechanisms produce cross-links connecting 2 polypeptide
chains.8,9
Previous studies in rats10,11 and patients12,13 with HF
have shown that whereas treatment with torasemide was
associated with a reduction in the amount of histologically
proven myocardial fibrosis (as assessed from the measure-
ment of the fraction of myocardial volume occupied by
collagen tissue or CVF), treatment with furosemide did
not. Thus, we hypothesized that torasemide, but not
furosemide, may also modify the quality of collagen (ie,
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reduction of insoluble collagen and collagen cross-linking)
in the myocardium of HF patients. In accordance with this
hypothesis, the following end points were defined: (1) to
test the effects of torasemide and furosemide, on top of the
recommended treatment for HF, on insoluble collagen and
collagen cross-linking in patients with HF, (2) to test the
effects of torasemide and furosemide on myocardial LOX
in these patients, and (3) to test the effects of torasemide
and furosemide on LV chamber stiffness in the same
patients.
Methods
An expanded version of the methods can be found in an online
supplement available at http://www.hypertensionaha.org.
Patients and Study Design
This was a prospective, randomized, parallel group study.
Twenty-four white patients with a previous diagnosis of chronic
HF were included. After randomization, 12 patients were assigned
to 10 to 20 mg torasemide daily (torasemide subgroup) and 12
patients to 20 to 40 mg furosemide daily (furosemide subgroup)
for 8 months. Ten patients from each subgroup completed the
study. Studies were performed on each patient at enrollment
(baseline) and 8 months after randomization. Septal endomyocar-
dial biopsies were obtained from autopsies of healthy subjects to
assess control reference values.
Echocardiographic Assessment
Two-dimensional echocardiographic imaging, targeted M-mode record-
ings, and Doppler ultrasound measurements were obtained from each
patient.
Biochemical Determination
Amino-terminal probrain natriuretic peptide (NT-proBNP) was mea-
sured in serum samples by an enzyme-linked immunosorbent assay
(Roche Diagnostics).
Histomorphologic and
Immunohistochemical Studies
Three transvenous endomyocardial biopsies were taken from the
middle area of the interventricular septum. The CVF was determined
by quantitative morphometry in sections stained with collagen-
specific picro-sirius red, as reported previously.14
To distinguish between cross-linked (insoluble) and noncross-
linked (soluble) collagen, a colorimetric procedure was used.15,16
The degree of cross-linking was calculated as the ratio between the
insoluble and the soluble forms of collagen. Immunohistochemical
analysis for LOX was performed using a mouse monoclonal anti-
body against LOX (R&D Systems).
Western Blot Studies
Western blot studies were performed as described recently17 using a
specific rabbit polyclonal antibody against LOX (R&D Systems).
Statistical Analysis
Differences between different groups were tested using a Student t
test for unpaired data or Mann–Whitney U test. Differences in
parameters before and after treatment within each subgroup of
patients were tested by a Student t test for paired data or Wilcoxon
signed-rank test. Categorical variables were analyzed by the 2
Fisher exact test. The correlation between continuously distributed
variables was tested by univariate regression analysis and bivariate
association. Data are expressed as meansSD and number of
patients. A P value 0.05 was considered statistically significant.
Analyses were performed with the SPSS 15.0 statistical package.
Figure 1. Immunostaining of LOX (in brown) in histological sec-
tions of myocardial specimens. The left panel corresponds to 1
control subject and shows very slight staining within some car-
diomyocytes and around some small intramural vessels. The
middle panel corresponds to 1 patient with chronic HF and
shows intense staining located in large areas of interstitial and
perivascular fibrosis and within many cardiomyocytes. The right
panel shows negative control for the correspondent primary
antibody omission. Magnification 100.
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Figure 2. The top panels show histograms
of myocardial LOX from patients with
chronic HF at baseline and 8 months after
randomization to furosemide (left) or to
torasemide (right). The bottom panels
show representative Western blot autora-
diograms of myocardial LOX from 2
patients with chronic HF at baseline and 8
months after randomization to furosemide
(left) or to torasemide (right).
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Results
Expression of Myocardial LOX in Controls and
the Whole Group of HF Patients
Figure 1 shows that whereas LOX was almost absent in the
myocardium of a control subject, it was highly expressed in
fibroblasts, areas of interstitial and perivascular fibrosis, and
cardiomyocytes in the myocardium of an HF patient. As
shown in Figure 2, one 32-kDa band corresponding to the
active form of LOX was identified in myocardial samples
from all HF patients. In contrast, the active form of LOX was
undetectable in myocardial samples from control subjects.
Types of Collagen and Collagen Cross-Linking in
Controls and the Whole Group of HF Patients
As shown in Table 1, the amounts of both insoluble and
soluble collagens were significantly higher in HF patients
than in control subjects. Whereas insoluble collagen corre-
sponded to 58.72.43% of total collagen in control hearts, it
represented 76.45.88% in failing hearts, a significant dif-
ference (P0.001). The degree of collagen cross-linking was
Table 1. Types of Collagen and Collagen Cross-Linking in
Control Subjects and the Whole Group of Patients With Chronic
HF
Parameters Control Group HF Group P
Insoluble collagen, g/mg 0.950.28 8.980.98 0.001
Soluble collagen, g/mg 0.660.17 2.760.63 0.001
Collagen cross-linking 1.430.29 3.471.03 0.001
Data are expressed as the mean valueSD. P for comparison between the
2 groups.
Table 2. Effects of Treatment on Clinical and Biochemical Parameters Assessed in the 2 Subgroups of Patients With Chronic HF
Parameters
Furosemide Subgroup Torasemide Subgroup
Final
PBaseline After TX P Baseline After TX P
Age, years 6710 669
Gender, men/women 8/2 8/2
Body weight, kg 79.512.4 82.413.3 0.432 80.79.1 82.09.2 0.507 0.461
Causes of HF, n
HHD 9 8
IHD 1 2
Types of HF, n
EF 0.40 3 5
EF 0.40 7 5
Medications, n
ACEIs or ARAs 10 10 10 10
-Blockers 10 10 10 10
Digoxin 2 2 3 3
Diuretics 0.642 0.717 0.002
Furosemide 10 10 0 0
Torasemide 0 0 10 10
Hctamiloride 1 1 0 0
SBP, mm Hg 13716 12113 0.001 14410 1287 0.003 0.098
DBP, mm Hg 8511 7311 0.004 929 755 0.001 0.900
LVMI, g/m2 18267 17349 0.289 15646 15442 0.750 0.237
RWT 0.360.04 0.330.03 0.050 0.340.09 0.350.09 0.200 0.492
LVEDV, mL 173.843 168.228.0 0.741 166.873 162.777 0.518 0.244
VE/VA 1.230.38 1.120.47 0.951 1.340.53 1.190.58 0.208 0.846
IVRT, ms 111.625.0 109.529 0.518 106.715 112.823 0.182 0.794
DT, ms 201.668.0 198.673.0 0.643 199.442 219.261 0.498 0.531
KLV, mm Hg/mL 0.1590.091 0.1650.091 0.570 0.1490.069 0.1270.053 0.502 0.287
EF 0.380.16 0.380.15 0.794 0.390.06 0.430.08 0.034 0.434
NYHA functional class 2.90.56 2.50.71 0.168 2.70.65 2.20.42 0.047 0.264
NT-proBNP, pg/mL 12391136 813503 0.352 1123706 540212 0.026 0.043
TX indicates treatment; HHD, hypertensive heart disease; IHD, ischemic heart disease; ACEIs, angiotensin-converting enzyme inhibitors; ARAs, angiotensin type I
receptor antagonists; Hct, hydrochlorothiazide; SBP, systolic blood pressure; DBP, diastolic blood pressure; LVMI, LV mass index; RWT, relative wall thickness; LVEDV,
LV end-diastolic volume; VE, maximum early transmitral velocity in diastole; VA, maximum late transmitral velocity in diastole; IVRT, isovolumic relaxation time; DT,
deceleration time; NYHA, New York Heart Association.
Data are expressed as the mean valueSD or number of patients. P for comparison of baseline values and values after treatment within each group. Final P for
comparison of values after treatment between the 2 groups of patients.
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significantly increased in the myocardium of HF patients
compared with control subjects (Table 1).
Effects of Treatment in the 2 Subgroups of
HF Patients
Clinical, Echocardiographic, and Biochemical Data
Clinical and echocardiographic characteristics of the 2 sub-
groups of patients at baseline are presented in Table 2. No
significant differences were observed between the subgroups
in the etiologies of HF. A depressed ejection fraction (EF;
below the normal cutoff value of 0.40) was observed in 70%
and 50% of patients from the furosemide subgroup and the
torasemide subgroup, respectively. Doppler criteria of dia-
stolic dysfunction were present in 50% and 70% of patients
from the furosemide subgroup and the torasemide subgroup,
respectively. An abnormally high LV chamber stiffness
constant (KLV) value was observed in 60% and 50% of
patients from the furosemide subgroup and the torasemide
subgroup, respectively. None of these differences reached
statistical significance.
Eight months after randomization, patients in the to-
rasemide subgroup and the furosemide subgroup received
mean daily dosages of 11.10.8 mg and 33.13.0 mg of
these agents, respectively. Baseline medications other than
loop diuretics were maintained unchanged during the treat-
ment period in the 2 subgroups of patients. No adverse effects
occurred during the study in either subgroup. The frequency
of complications (including hospitalizations and exacerba-
tions of HF) was similar in the 2 subgroups.
Although nonsignificant differences in the values of EF
were found after treatment in the 2 subgroups of treatment,
the frequency of patients showing normalization of this
parameter after treatment was higher (P0.025) in the
torasemide subgroup than in the furosemide subgroup (80%
versus 40%). In addition, although the final values of KLV
were similar in the 2 subgroups of patients, the frequency of
patients showing normalization of KLV after treatment was
greater (P0.009) in the torasemide subgroup than in the
furosemide subgroup (80% versus 0%). As shown in Table 2,
the levels of NT-proBNP decreased in the torasemide sub-
group but remained unchanged in the furosemide subgroup.
After treatment, NT-proBNP levels were lower in
torasemide-treated patients than in furosemide-treated pa-
tients. Finally, the New York Heart Association functional
class decreased in the torasemide subgroup and remained
unchanged in the furosemide subgroup (Table 2).
Expression of Myocardial LOX
No significant differences in the expression of LOX protein
were found at baseline between the 2 subgroups of patients
(Figure 2). Whereas the expression of LOX protein remained
unchanged in furosemide-treated patients (5.062.57 arbi-
trary densitometric units [A.D.U.] versus 5.082.61 A.D.U.),
it decreased (P0.034) in torasemide-treated patients
(4.861.78 versus 3.341.85 A.D.U.; Figure 2).
Total Collagen, Types of Collagen, and
Collagen Cross-Linking
No differences in the baseline values of CVF were observed
between the 2 subgroups. Whereas CVF decreased in the
torasemide subgroup after treatment (8.291.65% versus
4.240.74%; P0.001), it remained unchanged in the furo-
semide subgroup (7.933.05% versus 7.043.48%;
P0.549). Final values of CVF were lower (P0.001) in the
torasemide subgroup than in the furosemide subgroup.
The amounts of insoluble and soluble collagen and the
degree of cross-linking of the 2 subgroups of patients are
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Figure 3. The left panel shows the posi-
tive correlation (y0.2468.16) between
LOX and insoluble collagen in all patients
at baseline (F) and after treatment (E).
The right panel shows the positive corre-
lation (y0.3451.911) between LOX
and collagen cross-linking in all patients
at baseline (black circles) and after treat-
ment (white circles).
Table 3. Effects of Treatment on the Types of Collagen and Collagen Cross-Linking in the 2 Subgroups of Patients With Chronic HF
Furosemide Subgroup Torasemide Subgroup
Final
PParameters Baseline After TX P Baseline After TX P
Insoluble collagen, g/mg 9.101.26 9.690.99 0.012 8.880.63 7.502.26 0.045 0.028
Soluble collagen, g/mg 2.710.75 2.550.67 0.236 2.810.51 3.491.01 0.046 0.026
Collagen cross-linking 3.661.29 4.051.14 0.188 3.270.71 2.321.00 0.021 0.002
TX indicates treatment.
Data are expressed as the mean valueSD. P for comparison of baseline values and values after treatment within each group. Final P for comparison of values
after treatment between the 2 groups of patients.
Lo´pez et al Lysyl Oxidase and Heart Failure 239
 at UNIVERSIDAD DE NAVARRA on April 30, 2012http://hyper.ahajournals.org/Downloaded from 
presented in Table 3. No significant differences between the
2 subgroups of patients were found in these parameters at
baseline. Whereas insoluble collagen increased in
furosemide-treated patients (P0.012), it decreased in
torasemide-treated patients (P0.045). In addition, soluble
collagen increased (P0.046) in torasemide-treated patients
but remained unchanged in furosemide-treated patients. Thus,
whereas the degree of collagen cross-linking did not change
in furosemide-treated patients, it decreased (P0.021) in
torasemide-treated patients.
Association Studies
A positive correlation was found between the expression of
LOX protein and the amount of insoluble collagen (r0.603;
P0.004) and the degree of cross-linking (r0.661;
P0.000) in all patients at baseline and after treatment
(Figure 3). These correlations remained significant when we
excluded the influence of a number of potential confounding
factors (ie, age, body weight, systolic blood pressure, diastol-
ic blood pressure, LV mass index, LV diastolic volume, KLV,
and EF) in partial correlation analysis.
The amount of insoluble collagen was positively correlated
with KLV (r0.507; P0.007) in all patients at baseline and
after treatment (Figure 4). Similarly, the degree of cross-
linking was positively correlated with KLV (r0.452;
P0.002) in all patients at baseline and after treatment
(Figure 4). The 2 correlations remained significant when we
excluded the influence of a number of potential confounding
factors (ie, age, body weight, systolic blood pressure, diastol-
ic blood pressure, LV mass index, LV diastolic volume, and
EF) in partial correlation analysis.
Finally, negative correlations were found between LOX
and the deceleration time (r0.579; P0.001) and between
cross-linking and the deceleration time (r0.336;
P0.037) in all patients at baseline and after treatment. These
correlations also remained significant after excluding the
influence of the above potential confounding factors in partial
correlation analysis.
Discussion
The main findings of this study are as follows: (1) the
expression of LOX and the degree of collagen cross-linking
are abnormally increased in the myocardium of chronic HF
patients, (2) both LOX expression and collagen cross-linking
decrease in torasemide-treated chronic HF patients but re-
main unchanged in furosemide-treated chronic HF patients,
and (3) direct correlations exist between LOX and collagen
cross-linking and between collagen cross-linking and LV
stiffness in chronic HF patients. Collectively, these findings
show for the first time that LOX plays a critical role in
collagen alterations in the failing human heart.
The Cu-dependent enzyme LOX critically controls the
process whereby collagen molecules are assembled and
covalently cross-linked to one another, resulting in fibers with
increased material stiffness and greater resistance to degra-
dation. Whereas LOX mRNA upregulation has been reported
previously in explanted hearts of patients with idiopathic
dilated cardiomyopathy,18 low levels of collagen cross-
linking have been reported in the hearts of patients with the
same cardiac disease.19 However, none of these studies
explored whether the changes in LOX were simultaneously
associated with variations in the formation of insoluble
collagen (cross-linked). Here we show that an increase of
LOX was associated with an increase of insoluble collagen in
the human failing heart, suggesting that upregulation of the
enzyme is responsible for excessive collagen cross-linking
present in patients from this study. In support of this possi-
bility is our finding that in torasemide-treated patients, the
decrease in LOX was associated with the reduction in both
collagen cross-linking and the amount of insoluble collagen.
Dyshomeostasis of micronutrients such as Cu and zinc
(Zn) is part of the systemic illness that accompanies HF and
is simultaneously operative in promoting myocardial remod-
eling.20 In particular, the role of Cu in regulating the activity
of LOX and Cu/Zn-superoxide dismutase as well as the role
of Zn essential to the activity of angiotensin-converting
enzyme and matrix metalloproteinases is thought to be of
relevance for the regulation of collagen matrix. In this
conceptual framework, it is tempting to speculate that be-
cause of the different pharmacokinetic properties and phar-
macodynamic actions of torasemide and furosemide,21 these 2
compounds may differentially influence Cu and Zn ho-
meostasis, and this, in turn, may have a different impact on
the activity of LOX and other metalloenzymes in the heart.
Of interest, we found that in addition to its localization in
the interstitial space and fibroblasts, LOX was also expressed
in cardiomyocytes in patients with chronic HF. We have
shown recently that cardiomyocytes from chronic HF patients
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Figure 4. The left panel shows the posi-
tive correlation (y0.0320.050)
between insoluble collagen and KLV in all
patients at baseline (F) and after treat-
ment (E). The right panel shows the posi-
tive correlation (y0.0300.051)
between collagen cross-linking and KLV in
all patients at baseline (F) and after treat-
ment (E).
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express procollagen type I carboxy-terminal proteinase (PCP)
that regulates the synthesis of mature collagen type I,13 as
well as matrix metalloproteinase-1 that regulates the degra-
dation of collagen fibers.17 Collectively, these observations
suggest that in addition to fibroblasts, cardiomyocytes play a
major role in regulating collagen turnover in the failing
human heart.
LOX can be regulated at 3 levels: synthesis of LOX
precursor by fibroblasts and other fibrogenic cells,8 extracel-
lular conversion of the precursor into the active enzyme
because of the action of PCP,22,23 and direct stimulation of the
activity of the enzyme by cytokines such as transforming
growth factor-.24 We reported recently that PCP activation
was abnormally increased in the myocardium of chronic HF
patients and that torasemide, but not furosemide, decreased
myocardial PCP activation in these patients.13 In addition, it
has been reported that the expression of transforming growth
factor- is reduced in the myocardium of torasemide-treated
rats compared with control rats.10,11 It is thus tempting to
speculate that the reduction in LOX observed after treatment
in patients receiving torasemide can be related to the ability
of this compound to deactivate PCP or downregulate trans-
forming growth factor-.
Quantitative assessment of fibrosis in various murine
transgenic models, larger animal failure models, and even in
humans has not always found correlations between stiffness
and collagen content. In other studies, it has been demon-
strated that the relative ratio of insoluble to soluble collagen
(ie, the degree of cross-linking) is more important. For
example, in rats exposed to aortic binding, hypertrophy was
accompanied by increased total collagen, yet decreases in
insoluble/soluble collagen ratio, and no change in myocardial
stiffness.6 In contrast, spontaneously hypertensive rats had
elevated total collagen and higher insoluble/soluble ratio,
which correlated with chamber stiffening.6 Our findings that
LV stiffness is correlated with the amount of insoluble
collagen and the degree of cross-linking are consistent with
the notion that in the failing human heart, the quality of
collagen (specifically cross-linking) plays a key role in
translating quantity into mechanical stiffness and functional
performance of the left ventricle.
This hypothesis receives some support from changes in
clinical and biochemical parameters observed in treated
patients. In fact, a greater number of patients showed nor-
malization in KLV and EF in the torasemide subgroup than in
the furosemide subgroup. In addition, levels of NT-proBNP
decreased in torasemide-treated patients but not in
furosemide-treated patients. In this regard, it is interesting to
remark that myocardial stiffness has been shown to be the
most important determinant of the plasma BNP production in
patients with HF.25 Therefore, the ability of torasemide to
reduce LOX and collagen cross-linking may contribute to its
beneficial clinical impact on HF patients.
Several limitations of the current study must be recognized.
First, this was an individually randomized, parallel-group
study involving a small number of patients. In addition, it
must be recognized that therapy with -blockers, angioten-
sin-converting enzyme inhibitors, or angiotensin-receptor
antagonists may have influenced the findings. Second, al-
though we did not assess LOX precursor (ie, zymogen) or
LOX activity (ie, zymography), the associations found be-
tween LOX expression and insoluble collagen and collagen
cross-linking suggest that the activity of the enzyme may
parallel its expression in the failing human heart. Third, KLV
is difficult to measure in clinical practice, even with invasive
techniques. However, studies in animals26 and humans27 with
different hemodynamic conditions have demonstrated that the
deceleration time provides an accurate estimate of LV oper-
ating stiffness. Finally, it is important to consider the possi-
bility that the different pharmacology of furosemide and
torasemide, even in HF patients,21 may also contribute to the
differential effects of the 2 compounds on the cardiac
parameters tested in this study.
Perspectives
Findings from this study suggest a role for LOX upregulation
in the excess of collagen cross-linking present in patients with
chronic HF. In addition, our data suggest that the ability of
torasemide to correct both LOX overexpression and enhanced
collagen cross-linking may be involved in amelioration of
KLV in HF patients treated with this compound. These results
support the notion that therapeutic strategies directed not just
at reducing the amount of collagen but also at reducing
collagen cross-linking should be implemented in the preven-
tion of the adverse impact of myocardial fibrosis on cardiac
function in chronic HF patients.
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Supplemental Methods 
Patients and study design 
All subjects gave written, informed consent before participating in the study. The 
investigation conformed to the principles outlined in the Declaration of Helsinki. The 
study protocol was approved by the Institutional Ethics Committee of the Donostia 
University Hospital. 
Between January 2007 and January 2008, 34 consecutive Caucasian patients 
were screened for this study (Figure S1). All patients were required to have a previous 
diagnosis of chronic HF by the presence of a least 1 major and 2 minor criteria of the 
Framingham study during the last 6 months. Six patients with severe clinical conditions 
other than HF were excluded. Within the remaining 28 patients, 2 patients did not meet 
the inclusion criteria and 2 patient refused participation in the study. Whereas 85% of 
the 24 patients finally enrolled in the study had hypertensive heart disease, the 
remaining 15% showed ischemic heart disease. None of the patients had suffered from 
previous myocardial infarction.  
The study was a prospective, randomized, parallel group, study. Randomization 
was carried out by our division’s pharmacy that computer-generated the randomization 
sequence dispensed the study medication. All patients were randomly assigned to 
receive either torasemide or furosemide. After randomization, 12 patients were assigned 
to torasemide 10 to 20 mg daily (torasemide subgroup) and 12 patients to furosemide 20 
to 40 mg daily (furosemide subgroup) for 8 months. Existing recommended salt intake 
restriction (4 g/day) and concomitant HF medications (i.e., an angiotensin-converting 
enzyme inhibitor or an angiotensin-receptor antagonist, and a beta-adrenergic blocker) 
were continued during the study. None of the patients were treated with aldosterone 
antagonists. During the follow-up 1 patient in the furosemide subgroup died of 
progressive HF, and 1 patient in the furosemide subgroup and 2 patients in the 
torasemide subgroup discontinued the medication.  
A number of studies, including echocardigraphic evaluation, biochemical 
determinations and endomyocardial biopsy, were performed in each patient at 
enrolment (baseline) and 8 months after randomization. The investigators responsible 
for these studies were not aware of treatment of each patient. 
In the population sample of a previous study1 we measured the effects of either 
torasemide or furosemide on myocardial fibrosis CVF in HF patients. With the obtained 
CVF values and considering an α error of 0.05 and a β error of 0.20, we calculated that 
the minimal sample necessary to observe statistical differences between torasemide-
treated patients and furosemide-treated patients was of 9 patients in each group. 
A total of 100 autopsies performed at the University Clinic of Navarra were 
screened between January 2004 and January 2007. Ten hearts (6 men and 4 women, 
mean age 59 years, range 40 to 68 years) were selected from these cases according to 
the following criteria: 1) sudden death associated with traumatic injury in the absence of 
cardiac complications, 2) no medical history or physical and laboratory findings of 
cardiovascular disease, 3) absence of clinically recognized systemic disorders, 4) 
absence of atherosclerosis of the major coronary arteries, and 5) normal cardiac weight. 
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Septal endomyocardial biopsy specimens were taken from these hearts to assess control 
reference values of myocardial parameters evaluated in this study.  
Echocardiographic assessment 
Two-dimensional echocardiographic imaging, targeted M-mode recordings, and 
Doppler ultrasound measurements were obtained in each patient. Left ventricular mass 
was measured, and left ventricular mass index was calculated by dividing left 
ventricular mass by body surface area. Ejection fraction (EF) was calculated according 
to Quinones et al.2 The following pulsed Doppler measurements were obtained: 
maximum early transmitral velocity in diastole, maximum late transmitral velocity in 
diastole, the deceleration time of the early mitral filling wave, and isovolumic relaxation 
time.  
Left ventricular chamber stiffness (KLV) was calculated as the ratio squared 
according to the following equation:3 KLV = (0.07 : deceleration time)2. The upper 
normal limit for KLV previously defined in our laboratory for a normotensive population 
was of 0.151 mm Hg/ml. 
Biochemical determination 
Amino-terminal pro-brain natriuretic peptide (NT-proBNP) was measured in serum 
samples by an enzyme-linked immunosorbent assay using a commercial kit (Roche 
Diagnostics). All determinations were performed by duplicate. The inter- and intra-
assay coefficients of variation were 8 and 5%, respectively. The values of NT-proBNP 
obtained in our laboratory in a control population of 30 apparently healthy donors were 
163±8 pg/ml.  
Histomorphologic and immunohistochemical studies 
Three transvenous endomyocardial biopsies were taken from the middle area of the 
interventricular septum with a bioptome Cordis 96 cm (7-F) under fluoroscopic 
guidance after angiographic examination in each patient. Whereas two of the samples 
were employed for histomorphologic and immunohistochemical studies, the third of the 
samples was used for Western blot studies. 
 The collagen volume fraction (CVF) was determined by quantitative 
morphometry with an automated image analysis system in sections stained with 
collagen-specific picro-sirius red, as previously reported.4 All measurements were 
performed in duplicate by 2 independent observers. The inter- and intra-observer 
coefficients of variation were <4%. 
To distinguish between cross-linked (insoluble) and non-cross-linked (soluble) 
collagen a colorimetric procedure was employed.  First, a fast green-sirius red assay was 
performed to identify and quantify total collagen.5 In a second step, a sircol-based assay 
was performed to obtain and quantify soluble collagen.6 The amount of insoluble 
collagen was calculated by subtracting the amount of soluble collagen to the amount of 
total collagen. The degree of cross-linking was calculated as the ratio between the 
insoluble and the soluble forms of collagen. All measurements were performed in 
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duplicate. The inter- and intra-assay coefficients of variation were 5 and 3%, 
respectively. 
Immunohistochemical analysis for LOX was performed on formalin-fixed and 
paraffin-embedded sections. Immunohistochemical staining was performed by the 
avidin peroxidase-labeled dextran polymer method. Positive staining was visualized 
with DAB Plus (Boehringer Mannheim Corp.), and tissues were counterstained with 
Harris hematoxylin (Sigma). A mouse monoclonal antibody against LOX (R&D 
Systems) was used as the primary antibody. 
Western blot studies 
A 5-µg sample of total protein obtained from transvenous endomyocardial biopsies was 
processed for Western blot as recently described.7 A specific rabbit polyclonal antibody 
against LOX (R&D Systems) was used. Bands were detected by peroxidase-conjugated 
secondary antibodies (Amersham Biosciences) and visualized with the ECL-Plus 
chemiluminescence system (Amersham Biosciences). Autoradiograms were analyzed 
using an automatic densitometer (Molecular Imager FX, Bio-Rad). The blots were also 
probed with a monoclonal ß-actin antibody (Sigma) as a control for loading. Data are 
expressed as arbitrary densitometric units (A.D.U.) relative to beta-actin expression. All 
experiments were performed in duplicate. The inter- and intra-assay coefficients of 
variation were <5%. 
Statistical analysis 
Differences in cardiac parameters between the control group and the whole group of HF 
patients, and between the  2 subgroups of HF patients at baseline and after treatment 
were tested using a Student t test for unpaired data once normality was shown (Shapiro-
Wilks test); otherwise, a nonparametric test (Mann-Whitney U test) was used. 
Differences in parameters before and after treatment within each group of patients were 
tested by a Student t test for paired data once normality was shown (Shapiro-Wilks 
test); otherwise, a nonparametric test (Wilcoxon signed-rank test) was used. The 
Bonferroni correction was applied to the separate univariate tests for protection against 
Type I error. Categorical variables were analyzed by the chi-square (χ2) Fisher exact test 
when necessary. The correlation between continuously distributed variables was tested 
by univariate regression analysis and bivariate association (Spearman coefficient). 
Partial correlation coefficients were calculated to assess the independent relationship 
between the variable of interest (LOX and degree of collagen cross-linking) and KLV 
after adjustment for relevant covariates previously found to be associated with KLV in 
univariate regression models: age, body weight, systolic blood pressure, diastolic blood 
pressure, left ventricular mass index, left ventricular diastolic volume, and EF. Data are 
expressed as means ± SD, and number of patients. All statistical tests were two-sided 
with a significance level of 0.05. All statistical tests were performed with the SPSS 15.0 
statistical package. 
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Supplemental Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S1. Diagram showing the flow of participants through each stage of the study. 
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